quarter fiscal Thank across And everyone. you, programs. growth by the good year third growth quarter, across quarter to here over execution results, Brian. afternoon, driven delivered each I'm our on reflects the pleased be we today to compared strong performance third another COVID-XX discuss growth year the of segments business which of operational prior overall our In prior strategies. the excluding results to related against our including
to track. activities of committed Let to European We the me are of Management remain sell share exit of on progress on McKesson our our the immaterial. transactions an German assets to Alliance involved The in The Walgreens German contributed in were $X.X XX transaction revenues the joint billion of closed and on $XX in in Austrian joint related XXXX. ventures venture earnings million January to Quadrifolia to start Europe. our and fully business the we Today and sale our Austrian remaining adjusted Boots region the with update operating exit fiscal profit announced approximately 'XX.
fiscal including are anticipate will to classified quarter net XXXX. fiscal receipt divestiture in held European the as of Next fourth half The XXXX. will customary sell the McKesson's regulatory And first assets assets U.K. in satisfaction transactions close pursued the transaction sale. and to included closing pending close businesses the sell certain these the distribution We of retail conditions, in for of Group of to the to PHOENIX approvals.
accounting Our once pending adjusted fiscal accretion from per $X.XX segment. these recorded This sale XXXX earnings share accretion international of closed. guidance will is diluted includes is which for within held approximately conclude to resulting transaction of our $X.XX the each transactions, related
we for accretion to date not the Group share close related the sell. of $X.XX the accounting an Denmark adjusted XXXX, into agreement we approximately PHOENIX on held estimated the earnings only based anticipate fiscal Norway per and that for countries For transaction. diluted of remain current have currently sale to entered
discussed, through from dilution European principally anticipate offset to previously capital resulting all As we share deploy divestitures we'll repurchases.
more of retail only businesses Before sell. $XXX were of quarter after-tax quarter. our sale to declines remeasurement the sterling. one less details largely the I the impacted to the fair adjusted results British value, by third These recorded our I on and pound related to million results, assets provide out net GAAP point to gap item the distribution in only amount that a the the We U.K. want of driven cost charge carrying to additional in lower or for charges account in
quarter. adjusted for Slide be our consolidated can to with results now X. the Moving our Beginning results third which found on
manage our framework in December, creation. strategic shareholder value Day discussed our As is in on Investor the event focused for and and the financial long-term business we
financial combined adjusted This EPS and results. once quarter XXXX generate Our allocation. fiscal demonstrated growth, growth, is capital key framework three again leverage our by framework strong elements sustainable to operating organic third
to and leadership U.S. supporting we our efforts contribute business. to the and continues have COVID-XX the built domestic international and growth momentum across vaccine the Additionally, governments kitting
U.S. the U.S. diluted COVID-XX prior which partially items, COVID-XX from vaccine an performance was quarter our initial tests which in year. offset and year, XXXX programs to earnings for across the driven were profit primarily fiscal for of prior the from was generic strong with branded driven from mentioned programs and national government. gross the in personal of conversions. the our lower Adjusted to of Adjusted revenues quarter increase branded strong above kitting pharmaceutical in performance storage due benefited billion X% X% compared increase distribution, share line related operational $XX.X related profit per related by strong our the the by Consolidated Third of for products, segments. impact and the operating the prior $X.X share of volumes segment adjusted This compared the And expenses which items. $X.XX, increases, COVID-XX customers. segments. largely performance adjusted XX% price to from include billion operating to protective to divestitures led the in and quarter contribution XX% by operational the COVID-XX increased Adjusted held equipment $X.X increased retail higher by guidance, expenses contribution account increased growth result an count. year, a Pharmaceutical and impairments and increase in across prior the announced quarter was and year-over-year, the year-over-year. operating operational of previously X% accounting compared sale the billion international segment year excluding increased of XX% was
of Moving $XX the year. the million below compared XX% the interest improvement quarter line, to was expense and prior in
Our And diluted year-over-year. adjusted the a tax quarter. decrease of our $XXX.X wrapping shares for X% consolidated rate up million, weighted results, was XX.X% quarter average third were
of segment pharmaceutical generic XX% distribution were line service partially conversions. to of including volume access services conditions. which $XXX growth in our per our the the of on now technology which from provided In XX% profit increases was resulting branded million volumes. X contract price to partially with by third-party higher XX% driven COVID-XX revenue, The to government, account growth through a profit COVID-XX to by U.S. hospitals branded by higher specialty Pharmaceutical. prescription driven logistics inherent an solution distribution billion biopharma contribution increase XX. retail $X vaccine vaccines and Revenues in Slides the to related quarter, can and contribution from $X.XX of community products quarter Adjusted by Moving volumes share segment, third an and of from the increased and growth increased found distribution the operating the increase to the solutions. with a a in driven offset with year-over-year, million Starting be technology growth operating our revenues customers with from expectations. our benefit approximately U.S. of $XX $XXX results, prescription services, increased from national were XX% Adjusted billion,
and this We segment. increased across brands and margin year. growth in continue offerings experience inherent transaction our pleased that joined to broad the We're capabilities our this solutions, access volumes of the increasing to our related with number spectrum, platforms higher
due experienced increased services, also and in the prescription recovery volumes continued logistics volumes. We hub of our to
of U.S. the that vaccine prior and the ancillary of in in of $XXX fiscal contribution primary to incurred share Medical-Surgical from and care Solutions. kitting, to Revenues of PPE contribution increase Moving the an U.S. related $X.XX $X.X now by offset and for which business, XXXX distribution storage ancillary COVID-XX benefit care above our COVID-XX of inventory supplies increased COVID-XX from storage primary storage primary vaccines, the our year. by our X% impact per distribution growth for the to government program, vaccines provided impairment care COVID-XX tests year of lower in by and governments and as growth contribution supplies XX% driven a from quarter Adjusted business. expectations. driven original of businesses quarter, related partially kitting, an The were and the of billion, in profit charge revenue for to the contract extended approximately third from million supplies compared the to the was operating distribution care prior ancillary the in with kitting,
growth amortization. Next, The Walgreens the profit in Canadian in held contributed driven to adjusted in partially $X.X Canadian tests million, the the results. vaccines in businesses compared let were for with increases were depreciation international address pharmaceutical business classified the and distribution venture an distribution joint the by basis, for of quarter. as On Alliance. German $X.XX and FX European international COVID-XX X% earnings segment through our contribution reduction sale across in distribution wholesale me McKesson's in increase our adjusted of $XXX of and sale, offset the Boots business. to quarter retail to customer the segment, which Europe by strong the XX% by adjusted Revenues our in accounting volume Uncertain business, driven billion, new results as of the and year operating held assets increased and prior an
Moving for related on approximately expenses X% related will opioid quarter. the fiscal litigation XXXX expenses opioid corporate, $XXX be million. $XXX an We third increase litigation corporate to $XX of We year-over-year. that were million, adjusted expenses of incurred million anticipate
Let cash turn me We found now quarter on balance the of billion. a ended XX. to Slide $X.X which position, our with cash can be
generated the For the months nine first fiscal of free cash flow billion. $X.X year of we
Here to-date it made $XXX biopharma million of capital expenditures, pillars which included investments oncology of to support our and strategic services.
Austrian share the to anticipated remaining end business the our months of increased Day an For this German billion the approved $XXX we dividends. of of the and $X fiscal billion our the first quarter. returned fourth our authorization, the At and our program. to closure business, third in quarter repurchases joint shareholders, share completed our our announced in $X.X share nine included payment of billion executing quarter and increase the the cash Directors anticipate million U.K. share the up we existing sale repurchase of billion billion $X At fiscal we Board that year, $X.X repurchases share remains authorization. of on Investor to $X.X which December, sales of in fourth event of the in venture of the With of repurchase
$X.X approximately returning anticipate now XXXX. we result, share a shareholders through to repurchases fiscal in billion As
driving to performance Our our to with strong reinforces the combined value. of our shareholder operating return commitment capital shareholders,
XXXX. and XX assumptions of to XXXX in of full can for Let the our fiscal our remainder fiscal list transition outlook Slide A be XX. speak through me found
recovery continue We a prescription of anticipate volumes. to full
variants X% However, X% U.S. segment, is and we operating such to the prior XX% the the to In to as Omicron, to adjusted deliver year. COVID-XX persistence to anticipate Pharmaceutical and profit a revenue of its non-linear over increase leading trajectory. growth XX%
continue We our to fundamentals see business. U.S. stable in Pharmaceutical
in Specifically, branded generics consistent of our view In our remains with pharmaceutical our original of the guidance digits remains for increases single environment pricing both yet prior-year. and stable. competitive fiscal XXXX mid outlook
by vaccine U.S. related government's role and centralized distribution distribution the government, provided our guidance U.S. to Our the and includes volume the contribution program. schedule distributor aligned the CDC for as remains COVID-XX to a
fiscal of this XX%, continue assumes XX% profit we and business, our segment, in as of the as and of oncology profit an in a COVID-XX our anticipate XX% in we will anticipate will progress and segment, In Solutions distribution you to Technology our continue X% $X.XX the headwind to investments excluding We in approximately XXXX. represent adjusted operating to When solutions Prescription project And revenue to adjusted the volumes growth reflects profit surgical, in program. approximate leading outlook prior-year. XX% strong update growth medical and contribution existing operating adjusted revenue growth to and in reminder, momentum new X% growth. the XX% biopharma to our operating growth This Transitioning differentiated increased from customers. position vaccine the and across over XX%. we to XX% XX% growth, to
and $X.XX the to and U.S. government's of of supply from $X.XX impact excluding tests, related to ancillary contribution and storage programs growth the COVID-XX related to kits, distribution related over market, the we discussed $X.XX to prior-year. U.S. the which our $X.XX related includes to When net in these On outlook XX% in products. to impairments Our anticipate the and persist. businesses. of distribution items One reminder additional highly our we continues impacts call XX% the segment, November, competitive the to labor earnings PPE
expense support market service third and second our year. continued labor on labor talent slightly distribution of our related Medical in assumption for year, half the segment. to outlined fiscal U.S. and the in expectations quarter the through experienced approximately businesses remainder of the the $X.XX ensure of adjusted impact to Based higher We trends modest we fiscal expense second continuity also weighted our for strategy our impact anticipate year, continue the in to operating in of our half $X.XX an of
compared International contribution Walgreens the third as our to the reminder, this fiscal X% the a in Boots from to prior-year. in guidance Alliance quarter a reflects segment, growth German venture to the the impact X% of business with And as Finally, XXXX. joint revenue our decline of wholesale
of XX% segment for our accounting approximately to agreement held assets. $X.XX profit, resulting adjusted in of to related earnings operating the adjusted guidance European in certain our sale XXXX fiscal from XX%. For sell This includes reflects accretion to growth
to now the Turning consolidated view.
assumes X% XX% growth compared XX% revenue XXXX. adjusted and to XX% guidance to increased to Our profit fiscal operating growth
our previous unchanged we Our XX% we XX% $XXX corporate focus guidance related operating to million in to from recent improvement million rate highlighted of range the full-year an which our of million million $XXX tax expenses on at range effective event. anticipate adjustment leverage, to to $XXX $XXX the Investor remains and of Day
flow turn now deployment. me cash capital and to Let
execute continue cash businesses our growth. This flows sustainable drive strong to of in our pillars and share and capital generation as repurchases. allocation expect through balanced flow returning cash to long-term approach returns our growth to financial provides and investing even reinvesting strong capital flexibility free we biopharma on committed to continue support dividends to growing services, to shareholders oncology capital while a remaining strategic including We free
priority investment it grade underpins our rating Our a remains and flexibility. credit financial
acquisitions $X.X is software For billion expenses. anticipate property net which XXXX, fiscal capitalized flow we of continue of approximately and $X.X to free cash to billion,
larger a reminder, fiscal quarter of our cash of generate As a fourth portion flows our historically, we in year. the
divestiture the vary European flows working could which Our resulting timing impacted quarter-to-quarter, metrics activity. planned cash include by and timing, from capital of
million We also repurchases earlier. from weighted to shares X.X range outstanding fourth XXX diluted anticipated of XXX impact fiscal billion XXXX. the mentioned This million the share to anticipate now quarter includes for of
of remainder which to and guidance our previous range strong we for a of our range per share $XX.XX performance the the our of adjusted earnings $XX.XX is fiscal year-to-date year, to raising $XX.XX, are As narrowing and previous above our to outlook $XX.XX. result
corporate reflects to related the previous Investments share for distribution supplies, $X.XX an XXXX XXXX from and $X.XX, prior-year. to to per to is tests and products, diluted XX% related guidance segment. $X.XX XX% storage $X.XX attributable outlook the of Fiscal earnings of compared of earnings to in $X.XX adjusted gains vaccine related the PPE $X.XX ancillary Our government's U.S. $X.XX are updated our and following to growth $X.XX $X.XX adjusted losses impairments for also kitting items, to COVID-XX the Ventures approximately COVID-XX $X.XX increase with which associated includes share fiscal the to McKesson which contribution diluted the Equity and range per to to $X.XX, related to within distribution, from
COVID-XX items guidance our strong pull it XX% XXXX XX% forecast and When guidance provided outlook together, the equates weighted Approximately approximately previous $X.XX earnings increase $X.XX strong an adjusted opioid share lower and fiscal diluted approximately driven earnings business the the at NCI our sale Day, $X.XX $X.XX expense approximately includes to to performance growth performance compared per expenses, average $X.XX related indicates underlying held the this XXXX reduced for fiscal these of outlook in all Investor to impacts prior-year. $X.XX to shares of fiscal Excluding outstanding. from to our litigation to share XXXX increase interest both and leverage, you adjusted and operating accounting related results, diluted tests, following. by related and per over
time. this fiscal initial guidance XXXX Let are on me I providing XXXX. fiscal minute spend providing some want point that not at a just to out we thoughts
that through thought I items walk impact you as it However, some be of today. instructive sit XXXX we would fiscal here the could to
full present to XX we continue the expect many to First, unknowns, to recovery. continues COVID pandemic
Medical normal the with in However, of it the ancillary fiscal likely with anticipate to vaccines XXXX. government serve of Outside is storage to distribution are the continue to scheduled and vaccine quarterly centralized U.S. of the and U.S. distribution, and non-linear customer for Pharmaceutical into kitting in of as COVID-XX Pharmaceutical a segment. we XXXX the be our renewal July COVID-XX government activity supplies contracts expire contract segments, impact U.S. with U.S. cadence. In and to assist the Surgical could Solution to distributor it
will will rate COVID As a from to demand of the and COVID-XX levels. case the anticipate to closely impact tests, with be it levels this moderate associated continue relates we prior-year from
sale For the the transaction. closed first the half International segment, earnings held Group on we of anticipate estimated per the adjusted related Phoenix accretion in date to fiscal based the of diluted accounting XXXX share $X.XX for current for
litigation the assessment or in profit once and sale our determination expenses relatively in regarding related line proposed participation to We held a benefits transactions close. that until no settlement. XXXX will operating opioid guidance, remain will of accounting we revenue entity settlement record that for a these government the transactions have completed final We anticipate longer with fiscal adjusted
our investment outcome that our strength our deliver details the pleased services. growth financial biopharma in litigation will and remain we have to earnings fourth fiscal support continues of In third the more we continue about you heading opioid fundamentals two against results fiscal continue and of XXXX a May. outlook see at further the framework. the share about of We'll Overall, financial outlook. key into quarter to and determination closing, execute you remaining our results to we XXXX of with with update call We to successfully quarter as We we on anticipate strategic are oncology opportunities. and and underlying strategies expenses. McKesson and we strong fiscal stability our growth in the of optimistic strong business future
to company. patients thank and hard to their employees for our to thank on all want as things all work and We our that I most a focus of continue services the dedication. shareholders customers, diversified and matter healthcare you
Now I'll your to over questions. the operator turn the call for
